Daiichi Sankyo
Terry Katz is a seasoned professional in biostatistics and data management with over three decades of experience in the pharmaceutical and veterinary industries. Currently serving as Sr Director at Daiichi Sankyo, Inc., since May 2020, Terry provides strategic leadership to enhance the infrastructure and productivity of Biostatistics and Data Management. Previously, as Director at Merck Animal Health, expertise was applied in data management and statistics for veterinary biologicals, while also contributing to global health initiatives through the MSD Fellowship. Terry held the position of VP at ImClone Systems, directing strategies for oncology clinical trials and significantly expanding department size. Earlier roles include Sr Manager at PRA International and Manager at Schering-Plough Animal Health, where responsibilities included overseeing clinical trial statistics and regulatory submissions. Terry holds an MS in Statistics from Florida State University, a certificate in Management Information Systems from Kean University, and a BS in Microbiology from Penn State University.
This person is not in any teams
This person is not in any offices
Daiichi Sankyo
21 followers
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.